Markers of Oxidative Stress Present in Blood in Patients With Atrial Fibrillation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00142194|
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : September 27, 2013
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Atrial Fibrillation Inflammation Atrial Flutter|
Atrial fibrillation is an abnormal heart beat that starts in the upper parts of the heart and can cause stroke or death, if untreated. In general, treatments are not very effective with frequent relapses of the abnormal heart beats. One explanation for the high relapse rate is that the treatments might not address the underlying cause of atrial fibrillation.
Recently, we have found that atrial fibrillation is associated with increased oxidative stress in a particular part of the top parts of the heart, the left atrial appendage (LAA). Oxidative stress is a condition where abnormal oxygen forms are produced. These forms harm the cells of the heart, causing them to beat abnormally. Also, the inside of the heart becomes sticky and more likely to form blood clots. These clots, when they travel to the head, are thought to be the main cause of stroke in this condition. We have found increased oxidative stress and increased evidence of blood clotting in pig and mouse models of atrial fibrillation. We would like to see if these same findings are present in the human LAA.
In this study, we will compare blood and tissue markers of oxidative stress between patients with and without atrial fibrillation who are scheduled to undergo cardiac surgery. It is the expectation that participants with atrial fibrillation will have more abnormal markers of atrial fibrillation. This study requires participants to be seen during their routine preoperative visit, undergo a history and physical examination, give blood only once, and allow use of their discarded LAA. This tissue is routinely removed at surgery because its removal is thought to reduce the risk of stroke in patients who develop atrial fibrillation after the surgery. This happens in up to 50% of patients, thus providing the desire to remove the LAA.
|Study Type :||Observational|
|Actual Enrollment :||47 participants|
|Official Title:||Markers of Oxidative Stress Present in Blood in Patients With Atrial Fibrillation|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||November 2007|
|Actual Study Completion Date :||November 2007|
- atrial fibrillation (irregular heart beat coming from the upper chamber of the heart). To look at the differences between people who have irregular heart beats compared to those who do not have irregular beats. Study may last up until one year. [ Time Frame: 1 year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Cases must have atrial fibrillation documented on electrocardiographic recordings at the time of enrollment.
- Atrial fibrillation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00142194
|United States, Georgia|
|Emory University Hospital|
|Atlanta, Georgia, United States, 30322|
|Crawford Long Hospital|
|Atlanta, Georgia, United States, 30365|
|Principal Investigator:||Samuel C Dudley, M.D., Ph.D.||Veterans Administration/Emory University|
|Responsible Party:||Samuel C. Dudley, Jr., Principal Investigator, Emory University|
|Other Study ID Numbers:||
|First Posted:||September 2, 2005 Key Record Dates|
|Last Update Posted:||September 27, 2013|
|Last Verified:||September 2013|